Dr Bill Larkins
President, Injectables
2023
Appointed
2022
Joined Hikma
American
Nationality
Role: Bill was appointed as President of Hikma’s Injectables business in September 2023. Bill has extensive experience in the sterile injectable generic market, having previously served as Chief Executive Officer of Custopharm, which was acquired by Hikma in 2022, and until September 2023 served as Hikma’s Senior Vice President, R&D, Injectables.
Qualifications: BSc in Chemistry from Purdue University and a PhD in Analytical Chemistry from The Ohio State University.
